» Articles » PMID: 29556872

Embolic Strokes of Undetermined Source in a Cohort of Polish Stroke Patients

Overview
Journal Neurol Sci
Specialty Neurology
Date 2018 Mar 21
PMID 29556872
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

We aimed to provide a descriptive analysis of embolic stroke of undetermined etiology (ESUS) population based on a long-term prospective stroke registry. We retrospectively analyzed data collected in a detailed registry regarding consecutive patients admitted for first-ever ischemic stroke (IS) between January 2001 and December 2015. We used Org 10172 in Acute Stroke Treatment classification supplemented with ESUS criteria proposed by the Cryptogenic Stroke/ESUS International Working Group. Within the ESUS group, we additionally compared patients ≤ 60 and > 60 years of age. During the study period, there was a total of 3008 (1615 females and 1393 males) admissions of first-ever strokes. The most frequent cause was undetermined (38.7%), followed by cardioembolic (27.7%), large artery atherosclerosis (18.2%), small vessel disease (11.9%), and other determined (3.6%). We identified 326 patients as ESUS, which accounted for 10.8% of all strokes and 28% of strokes of undetermined etiology. ESUS patients were the youngest. Compared to all types of stroke but for those with small vessel disease, ESUS patients were most often independent before stroke and had the least severe neurological deficit at admission and the best outcome at discharge. ESUS patients ≤ 60 years were more frequently independent at discharge than ESUS patients > 60 years. Approximately 11% of patients from our registry met ESUS criteria. ESUS patients were younger when compared to all other stroke etiologies, suffered less severe strokes, and had more favorable outcome at discharge than other groups except for those with small vessel disease strokes.

Citing Articles

Periodic Limb Movements during Sleep in Acute Stroke: Prevalence, Severity and Impact on Post-Stroke Recovery.

Plomaritis P, Theodorou A, Michalaki V, Stefanou M, Palaiodimou L, Papagiannopoulou G J Clin Med. 2023; 12(18).

PMID: 37762823 PMC: 10531709. DOI: 10.3390/jcm12185881.


Review and update of the concept of embolic stroke of undetermined source.

Diener H, Easton J, Hart R, Kasner S, Kamel H, Ntaios G Nat Rev Neurol. 2022; 18(8):455-465.

PMID: 35538232 DOI: 10.1038/s41582-022-00663-4.


Characteristics and Outcomes of Younger Adults with Embolic Stroke of Undetermined Source (ESUS): A Retrospective Study.

Al Khathaami A, Al Bdah B, Alnosair A, Alturki A, Alrebdi R, AlWayili S Stroke Res Treat. 2019; 2019:4360787.

PMID: 31885851 PMC: 6914878. DOI: 10.1155/2019/4360787.


FTIR, Raman and AFM characterization of the clinically valid biochemical parameters of the thrombi in acute ischemic stroke.

Blat A, Dybas J, Chrabaszcz K, Bulat K, Jasztal A, Kaczmarska M Sci Rep. 2019; 9(1):15475.

PMID: 31664105 PMC: 6820737. DOI: 10.1038/s41598-019-51932-0.


Predictors of poor outcome in embolic stroke of undetermined source.

Al Khathaami A, Al Bdah B, Alnosair A, Alturki A, Alrebdi R, AlWayili S Neurosciences (Riyadh). 2019; 24(3):164-167.

PMID: 31380814 PMC: 8015519. DOI: 10.17712/nsj.2019.3.20190005.


References
1.
Li L, Yiin G, Geraghty O, Schulz U, Kuker W, Mehta Z . Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015; 14(9):903-913. PMC: 5714616. DOI: 10.1016/S1474-4422(15)00132-5. View

2.
Hart R, Catanese L, Perera K, Ntaios G, Connolly S . Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017; 48(4):867-872. DOI: 10.1161/STROKEAHA.116.016414. View

3.
Grau A, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S . Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001; 32(11):2559-66. DOI: 10.1161/hs1101.098524. View

4.
Bonita R, Beaglehole R . Recovery of motor function after stroke. Stroke. 1988; 19(12):1497-500. DOI: 10.1161/01.str.19.12.1497. View

5.
Geisler T, Poli S, Meisner C, Schreieck J, Zuern C, Nagele T . Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke. 2016; 12(9):985-990. DOI: 10.1177/1747493016681019. View